Search Results

June 18, 2013

Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting

Late-Breaking Phase 3 Results and Health Economics Data are Among 17 Accepted Presentations

May 9, 2011

New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis

Study Findings Demonstrate Clinical Response with REMICADE in Pediatric Patients Who Have Not Responded to Conventional Therapy

Innovative Medicine

June 5, 2012

New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease

Study Findings Include Results of SIMPONI Intravenous Formulation on Rheumatoid Arthritis Associated Fatigue

Innovative Medicine

June 24, 2013

Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes

Phase 3 Results for INVOKANA™ Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure

Innovative Medicine

May 25, 2011

New Four Year STELARA™* Data Show Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis

Results Presented from the STELARA™ Clinical Development Program Also Demonstrate Consistency of Response across Multiple Ethnic Populations

Innovative Medicine

July 16, 2012

Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis

Search Results

No Results

Recently Viewed

Search Results

Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting

New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis

New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease

Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes

New Four Year STELARA™* Data Show Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis

Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis